Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of targeted oxidative therapeutic formulation in treatment of burns

A technology of oxidizing agents and pharmaceutical preparations, especially in the field of scar tissue caused by burns, reduction of scar tissue, pharmaceutical compositions or preparations, which can solve problems such as preparation or storage risks, and no clinical effectiveness

Inactive Publication Date: 2007-08-01
罗伯特·F·霍夫曼
View PDF10 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, their preparation or storage is extremely dangerous
[0024] In addition, geraniol (a linear monoterpene alcohol) ozonide dissolved in water or dimethylsulfoxide ("DMSO") was effective in three cases of viral varicella shingles (shingles) and in two cases of simplex Did not show any clinical effectiveness in Herpes Simplex dermatitis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of targeted oxidative therapeutic formulation in treatment of burns
  • Use of targeted oxidative therapeutic formulation in treatment of burns
  • Use of targeted oxidative therapeutic formulation in treatment of burns

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0076] Embodiment 1. The ozonolysis of unsaturated hydrocarbon

[0077] Ozonolysis of alkenes can be performed in solution or neat. In either case, cooling of the reaction mixture is critical to prevent explosive decomposition of the peroxidized product of the reaction.

[0078] The following general procedure is typical for the ozonolysis of liquid alkenes.

[0079] The alkene (2 moles) was charged to a 1 liter flask with a magnetic stirrer bar and the apparatus was weighed. Surround the flask with a cold bath (ice-water or ice-salt). Once the contents have cooled below 5°C, agitation is started and a stream of ozone in dry oxygen (typically 3% ozone) is passed through the mixture. Dispersing the ozonated oxygen with glass frit is advantageous, but not necessary for stirred solutions.

[0080] Periodically the gas flow was stopped and the reaction flask was weighed or the reaction mixture was sampled. Then restart the airflow.

[0081] Once the mass of the reaction flas...

Embodiment 2

[0084] The preparation of embodiment 2 pharmaceutical preparations

[0085] A preferred pharmaceutical formulation of the invention is prepared as follows:

[0086] (1) Bubble 120 mg / L of ozone / pure oxygen mixture upward through alkadiene alcohol: 3,7-dimethyl-2,6-octadien-1-ol at 1 liter of gas per hour (geraniol);

[0087] (2) keep the temperature of the reaction at about 5°C;

[0088] (3) Take out a small aliquot of reaction product every hour, and measure the formation of peroxide species or reaction product with H1NMR;

[0089] (4) Stopping the reaction when more than 50% of the available unsaturated bonds have reacted;

[0090] (5) Dilute the product mixture with dimethyl sulfoxide (1:10) to obtain a solution or dispersion;

[0091] (6) Before using in the target biological system, the mixture of hematoporphyrin, rose bengal and menaquinone dry powder is added to the solution or dispersion, and the amount added is enough to make each component dispersed therein be in...

Embodiment 3

[0092] The example of embodiment 3 pharmaceutical preparations

[0093] Two preferred formulations are as follows:

[0094] weight%

[0095] *Determined by mass spectrometry

[0096] weight%

[0097] *Determined by mass spectrometry

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a pharmaceutical formulation and its use. The pharmaceutical formulation contains peroxidic species or reaction products resulting from oxidation of an alkene, such as geraniol, by an oxygen-containing oxidizing agent, such as ozone; a penetrating solvent, such as dimethylsulfoxide ('DMSO'); a dye containing a chelated metal, such as hematoporphyrin; and an aromatic redox compound, such as benzoquinone. The pharmaceutical formulation is used to effectively resolve scar tissue, particularly scar tissue resulting from a burn, and to treat patients with bum-related injuries.

Description

[0001] related application [0002] This application claims priority to U.S. Provisional Patent Application Serial No. 60 / 582,343, entitled "Use of Targeted Oxidative Therapeutic Agents in the Treatment of Burns," filed June 23, 2004, which is hereby adopted in its entirety incorporated herein by reference. technical field [0003] The present invention relates to substances comprising peroxidic species or oxidation products, processes for their preparation, and their use. More specifically, the present invention relates to pharmaceutical compositions or formulations comprising: peroxide species or reaction products produced by oxidation of alkene compounds in liquid form or in solution by oxygen-containing oxidizing agents; dyes containing chelated metals and aromatic redox compounds. The invention also relates to the preparation of said pharmaceutical preparation and its use for reducing scar tissue, especially scar tissue caused by burns. Background technique [0004] ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/335A61P17/02
CPCA61K31/335A61K9/0014A61P17/02A61K2300/00
Inventor 罗伯特·F·霍夫曼
Owner 罗伯特·F·霍夫曼
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com